AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7392895 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 30274549 — intervention group
Group type: EXPERIMENTAL
Intervention: CGBP + MP + BP with barbell (O1)
Number of subjects: 12
Study 30274549 — intervention group
Group type: EXPERIMENTAL
Intervention: BP positioned last in the sequence (O1 and O3)
Number of subjects: 12
Study 30274549 — intervention group
Group type: EXPERIMENTAL
Intervention: CGBP (O1 and O3)
Number of subjects: 12
Study 30274549 — intervention group
Group type: EXPERIMENTAL
Intervention: CGBP with Smith machine
Number of subjects: 12
Study 31012909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0
Study 31012909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28350280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33–34°C)
Number of subjects: 111
Study 28350280 — intervention group
Group type: COMPARATOR
Intervention: Control (hemicraniectomy alone)
Number of subjects: 111
Study 25957663 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message immunization reminders
Number of subjects: 57
Study 25957663 — intervention group
Group type: COMPARATOR
Intervention: Healthy baby messages (Control)
Number of subjects: 57
Study 24624851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and PCA with Trimeperidine
Number of subjects: 80
Study 24624851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 microg each 12 hours intramuscular) and PCA with Trimeperidine
Number of subjects: 80
Study 24624851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam, Ketoprofen and PCA with Trimeperidine
Number of subjects: 80
Study 24624851 — intervention group
Group type: COMPARATOR
Intervention: PCA with Trimeperidine as monotherapy
Number of subjects: 80
Study 21352357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic fluids (50-70 mmol/L tonicity)
Number of subjects: 125
Study 21352357 — intervention group
Group type: COMPARATOR
Intervention: Isotonic fluids (156 mmol/L tonicity)
Number of subjects: 125
Study 19720211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study 19720211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 60
Study 19720211 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 60
Study 17473654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m intravenously [IV] supplemented with vitamin B12 injections and oral folic acid)
Number of subjects: 541
Study 17473654 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m IV)
Number of subjects: 541
Study 17473654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 541
Study 15212837 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein-depleted plasma
Number of subjects: 0
Study 15212837 — intervention group
Group type: COMPARATOR
Intervention: Lipoprotein-free sAbeta
Number of subjects: 0
Study 11824878 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists (specific drugs not mentioned)
Number of subjects: 274
Study 11824878 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 274
Study 9686732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 299
Study 9686732 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 299
Study 8021375 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/gm) combined with cyclosporine (2 mg/kg/day)
Number of subjects: 69
Study 8021375 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (vehicle of calcipotriol) combined with cyclosporine (2 mg/kg/day)
Number of subjects: 69
Study 2671217 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 120
Study 2671217 — intervention group
Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 120
Study 2671217 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy (in adults)
Number of subjects: 120
Study 2671217 — intervention group
Group type: COMPARATOR
Intervention: Dissection tonsillectomy (in adults)
Number of subjects: 120
Study 1095118 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 113
Study 1095118 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology
Number of subjects: 113
Study 1095118 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 113
Study 1095118 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 113
Study 1095118 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 113
Study 1095118 — intervention group
Group type: COMPARATOR
Intervention: Multifactorial computer analysis
Number of subjects: 113
Study 31378074 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital tools for integrated personalized diabetes management (iPDM)
Number of subjects: 907
Study 31042581 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (PegIFN)
Number of subjects: 1823
Study 31042581 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analogues (NUCs)
Number of subjects: 1823
Study 28159005 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Wellness after Cancer Program (WWACP) - a digitised multimodal lifestyle intervention focusing on health education and promotion over 12 weeks.
Number of subjects: 351
Study 27012084 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedure A (specific procedure not detailed)
Number of subjects: 94
Study 27012084 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedure B (specific procedure not detailed)
Number of subjects: 94
Study 23114568 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Asperger's syndrome (AS)
Number of subjects: 0
Study 23114568 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 21207250 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 102
Study 21207250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18292438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine infusion at a rate ranging from 6 to 10 microg x kg(‐1) x h(‐1)
Number of subjects: 6
Study 18292438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine infusion
Number of subjects: 6
Study 15653651 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosynovectomy (RSV)
Number of subjects: 0
Study 15653651 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of radiopharmaceuticals
Number of subjects: 0
Study 14522736 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg Fe as ferrous sulfate)
Number of subjects: 513
Study 14522736 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 513
Study 14522736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 10762110 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Diskhaler twice daily for 5 days
Number of subjects: 356
Study 10762110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 10762110 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 356
Study 8697891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.d.)
Number of subjects: 0
Study 8697891 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (1 g t.d.s.)
Number of subjects: 0
Study 1618211 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg per day
Number of subjects: 57
Study 1618211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 1618211 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 57
Study 6376210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (Fabrol)
Number of subjects: 0
Study 6376210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29494476 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 30
Study 29494476 — intervention group
Group type: EXPERIMENTAL
Intervention: STAND
Number of subjects: 30
Study 29494476 — intervention group
Group type: EXPERIMENTAL
Intervention: BOARD
Number of subjects: 30
Study 27189956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 30
Study 27189956 — intervention group
Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 30
Study 27189956 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO (secondary attempt with ethanol)
Number of subjects: 30
Study 24662153 — intervention group
Group type: EXPERIMENTAL
Intervention: Three triangular dermal flaps technique
Number of subjects: 50
Study 24662153 — intervention group
Group type: COMPARATOR
Intervention: Control series (standard technique)
Number of subjects: 50
Study 23046783 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused group
Number of subjects: 0
Study 23046783 — intervention group
Group type: COMPARATOR
Intervention: Fact-focused group
Number of subjects: 0
Study 20298996 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) in patients with prior CABG
Number of subjects: 128
Study 20298996 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) in patients without prior CABG
Number of subjects: 128
Study 20298996 — intervention group
Group type: EXPERIMENTAL
Intervention: IRA as a bypass graft in prior CABG patients
Number of subjects: 128
Study 20298996 — intervention group
Group type: EXPERIMENTAL
Intervention: IRA as a native vessel in prior CABG patients
Number of subjects: 128
Study 20298996 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality in prior CABG patients
Number of subjects: 128
Study 20298996 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite 90-day death/congestive heart failure/shock in prior CABG patients
Number of subjects: 128
Study 18843433 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months exercise training
Number of subjects: 60
Study 15959799 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained runners
Number of subjects: 20
Study 12634981 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 105
Study 12634981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 11262673 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually focused intervention (n=48)
Number of subjects: 97
Study 11262673 — intervention group
Group type: EXPERIMENTAL
Intervention: Family focused intervention (n=49)
Number of subjects: 97
Study 11262673 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (family and individually focused)
Number of subjects: 97
Study 9543661 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 1121
Study 9543661 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment participation
Number of subjects: 1121
Study 9543661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention enrollment
Number of subjects: 1121
Study 8448458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diaries
Number of subjects: 24
Study 8448458 — intervention group
Group type: COMPARATOR
Intervention: Pencil and paper diaries
Number of subjects: 24
Study 8448458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diary methods
Number of subjects: 24
Study 3915163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (single dose)
Number of subjects: 24
Study 3915163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (multidose, three times daily)
Number of subjects: 24
Study 3915163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 24
Study 3915163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multidose, three times daily)
Number of subjects: 24
Study 29791315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical chorioamnionitis
Number of subjects: 9391
Study 27816696 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 31
Study 27816696 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 31
Study 27816696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24858952 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduced rapid-acting insulin dose
Number of subjects: 8
Study 24858952 — intervention group
Group type: COMPARATOR
Intervention: Full rapid-acting insulin dose
Number of subjects: 8
Study 22548359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft (BDX)
Number of subjects: 45
Study 22548359 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 45
Study 20302978 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective analgesia (1.6g modified release ibuprofen)
Number of subjects: 122
Study 20302978 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (400mg conventional ibuprofen)
Number of subjects: 122
Study 20302978 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective analgesia
Number of subjects: 122
Study 20302978 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 122
Study 20302978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 18328014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g daily for 3 months)
Number of subjects: 55
Study 18328014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 18328014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed + additional oat bran fiber (not specified)
Number of subjects: 55
Study 15883267 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 microg TIW
Number of subjects: 605
Study 15883267 — intervention group
Group type: COMPARATOR
Intervention: 30 microg QW to 44 microg TIW
Number of subjects: 605
Study 12860897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) in subjects with mutations
Number of subjects: 12
Study 12860897 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study 10100079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinyloestradiol
Number of subjects: 24
Study 10100079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg oestrone sulphate
Number of subjects: 24
Study 10100079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg oestrone sulphate
Number of subjects: 24
Study 10100079 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study 10100079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oestrone
Number of subjects: 24
Study 10100079 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisynthetic oestrogen
Number of subjects: 24
Study 8914356 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate 0.05% cream
Number of subjects: 40
Study 8914356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1796230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin at 100 mcg/kg
Number of subjects: 1979
Study 1796230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) at 3 and 6 mg/kg
Number of subjects: 1979
Study 1796230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1979
Study 6095635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-bran diet
Number of subjects: 20
Study 6095635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean diet
Number of subjects: 20
Study 6095635 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study 30653044 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS bot intervention group
Number of subjects: 159
Study 30653044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 30138012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustain group (internal supervision)
Number of subjects: 168
Study 30138012 — intervention group
Group type: COMPARATOR
Intervention: External Supervision group (external supervision)
Number of subjects: 168
Study 27108247 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) history
Number of subjects: 4038
Study 25251800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing exercise regimen using a rowing ergometer
Number of subjects: 29
Study 25251800 — intervention group
Group type: COMPARATOR
Intervention: Chest physical therapy program
Number of subjects: 29
Study 22265215 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 483
Study 22265215 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACG)
Number of subjects: 483
Study 20136919 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Boswellic acids (0.5% BAs)
Number of subjects: 15
Study 20136919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (base cream without BAs)
Number of subjects: 15
Study 18377783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets
Number of subjects: 0
Study 18377783 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diets
Number of subjects: 0
Study 15814545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 15814545 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 205
Study 15814545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tacrolimus and cyclosporin-ME
Number of subjects: 205
Study 12168963 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O pneumoperitoneum
Number of subjects: 103
Study 12168963 — intervention group
Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum
Number of subjects: 103
Study 12168963 — intervention group
Group type: COMPARATOR
Intervention: Postoperative narcotic or ketorolac use
Number of subjects: 103
Study 10745577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine treatment
Number of subjects: 25
Study 10745577 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study 7557825 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1974940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening between the 16th and 20th gestational weeks
Number of subjects: 9310
Study 1974940 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (control group)
Number of subjects: 9310
Study 1974940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 9310
Study 1974940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (twins)
Number of subjects: 9310
Study 1974940 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (control group, twins)
Number of subjects: 9310
Study 365775 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU of the influenza subunit vaccine
Number of subjects: 0
Study 365775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU of the influenza subunit vaccine
Number of subjects: 0
Study 365775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU of the influenza subunit vaccine
Number of subjects: 0
Study 365775 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection
Number of subjects: 0
Study 30641707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in male subjects
Number of subjects: 1008
Study 30641707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in female subjects
Number of subjects: 1008
Study 28278391 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (110/50 μg once daily)
Number of subjects: 0
Study 28278391 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/500 μg twice daily)
Number of subjects: 0
Study 28278391 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Number of subjects: 0
Study 28278391 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone
Number of subjects: 0
Study 26133147 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft (FGG)
Number of subjects: 15
Study 26133147 — intervention group
Group type: COMPARATOR
Intervention: Modified Apically Repositioned Flap (MARF)
Number of subjects: 15
Study 23252768 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 0
Study 23252768 — intervention group
Group type: COMPARATOR
Intervention: MAL
Number of subjects: 0
Study 23252768 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA (narrow wavelength LED lamps)
Number of subjects: 0
Study 23252768 — intervention group
Group type: COMPARATOR
Intervention: MAL (narrow wavelength LED lamps)
Number of subjects: 0
Study 21069358 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta 1 levels in patients with AF (n=107)
Number of subjects: 401
Study 21069358 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta 1 levels in patients with aCHF (n=122)
Number of subjects: 401
Study 21069358 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for TGF-beta 1
Number of subjects: 401
Study 21069358 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta 1 with left atrial diameter
Number of subjects: 401
Study 21069358 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta 1 with NT-proBNP
Number of subjects: 401
Study 19028707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) of ketamine
Number of subjects: 50
Study 19028707 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 50
Study 17265030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (250 mg every 6 h for 3 days, then 1 mg/kg prednisolone orally for 14 days)
Number of subjects: 31
Study 17265030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml normal saline every 6 h for 3 days, then placebo for 14 days)
Number of subjects: 31
Study 14751428 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 14751428 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 60